33 Citazioni (Scopus)

Abstract

The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors.
Lingua originaleEnglish
pagine (da-a)879-887
Numero di pagine9
RivistaDefault journal
Volume3
Stato di pubblicazionePublished - 2011

Fingerprint

erbB-1 Genes
Genes
Gene Dosage
Glioma
Antineoplastic Agents
Protein-Tyrosine Kinases
Colorectal Neoplasms
Ovary
Lung Neoplasms
Neoplasms
Colon
Breast
Neck
Head
Monoclonal Antibodies
Lung
Mutation
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cita questo

@article{584e5c25099e45aabbe631a3126f0b72,
title = "EGFR genomic alterations in cancer: prognostic and predictive values",
abstract = "The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors.",
author = "Marianna Terrasi and Antonio Russo and {Di Gaudio}, Francesca and Giuseppe Bronte and Nicolo' Gebbia and Gaspare Gulotta and Sergio Siragusa and Massimo Cajozzo and Nicola Sivestris and Sergio Siragusa and Corrado Ficorella and Sergio Rizzo",
year = "2011",
language = "English",
volume = "3",
pages = "879--887",
journal = "Default journal",

}

TY - JOUR

T1 - EGFR genomic alterations in cancer: prognostic and predictive values

AU - Terrasi, Marianna

AU - Russo, Antonio

AU - Di Gaudio, Francesca

AU - Bronte, Giuseppe

AU - Gebbia, Nicolo'

AU - Gulotta, Gaspare

AU - Siragusa, Sergio

AU - Cajozzo, Massimo

AU - Sivestris, Nicola

AU - Siragusa, Sergio

AU - Ficorella, Corrado

AU - Rizzo, Sergio

PY - 2011

Y1 - 2011

N2 - The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors.

AB - The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors.

UR - http://hdl.handle.net/10447/112695

M3 - Article

VL - 3

SP - 879

EP - 887

JO - Default journal

JF - Default journal

ER -